本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重庆莱美药业股份有限公司（以下简称"公司"、"莱美药业"）与全资子 公司重庆市莱美医药有限公司（以下简称"莱美医药"）前期收到长春新区人民 法院出具的《民事判决书》（2022）吉 0193 民初 85 号，该诉讼事项一审判决具 体内容详见公司在巨潮资讯网发布的《关于公司及子公司诉讼事项一审判决结果 的公告》（公告编号 2023-025）。公司与莱美医药因不服一审判决结果，分别向 吉林省长春市中级人民法院提起上诉，在收到吉林省长春市中级人民法院出具的 《交纳诉讼费用通知书》后，已均于 2023 年 8 月 18 日缴纳上诉费，现将有关情 况公告如下： 证券代码：300006 证券简称：莱美药业 公告编号：2023-028 重庆莱美药业股份有限公司 关于公司及子公司诉讼事项进展暨提起上诉的公告 3、被上诉人（一审原告）：长春海悦药业股份有限公司（以下简称"海悦 药业"） 法定代表人：任泽波，董事长兼总经理（截至目前，董事长兼总经理已变更 为辛运宏） 4、管辖法院：吉林省长春市中级人民法院 5、案件所处的诉讼阶段：已缴 ...

关于控股子公司获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、获得政府补助的基本情况 重庆莱美药业股份有限公司（以下简称"公司"）控股子公司西藏莱美德济 医药有限公司（以下简称"莱美德济"）依据《拉萨经济技术开发区关于进一步 促进产业高质量发展 1+N 政策的实施意见》的相关规定，于 2023 年 8 月 14 日 收到西藏拉萨经济技术开发区管理委员会下发的 2022 年度产业发展扶持资金， 共计 41,593,315.00 元，占公司最近一年经审计净利润绝对值的 54.52%。本次获 得政府补助具体情况如下： | | | | | | | | | 是 否 与公 | 是否 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 获得补 | 提供补助 | 补助的原 | 补助 | 补助金额 | | 计入 | 是否 | 司 日 常经 | 具有 | | 助的主 | | | | | 补助依据 | 会计 | 实际 | | | | | 的主体 | 因或项目 | 形式 | （元） ...

Revenue and Financial Performance - Revenue for the first quarter of 2023 increased by 14.06% to 226,654,528.42 yuan compared to the same period last year[2] - Total revenue for the quarter was 226.65 million yuan, an increase from 198.71 million yuan in the same period last year[20] - Sales revenue from goods and services was 220.995 million USD, a decrease from 259.388 million USD in the previous year[24] Net Profit and Loss - Net loss attributable to shareholders of the listed company decreased to -3,634,060.91 yuan from -26,403,512.18 yuan year-over-year[2] - Net profit for the first quarter of 2023 was -7.606 million USD, a significant improvement from -28.991 million USD in the same period last year[21] Cash Flow - Operating cash flow turned positive at 9,591,286.80 yuan, compared to -12,698,605.55 yuan in the same period last year[2] - Net cash flow from operating activities was 903.78 million yuan, compared to 846.29 million yuan at the beginning of the year[16] - Operating cash flow for the first quarter of 2023 was 9.591 million USD, compared to -12.699 million USD in the same period last year[25] - Investment cash flow improved significantly, with a net inflow of 38,635,590.92 yuan compared to a net outflow of 81,194,088.89 yuan last year[11] - Investment cash flow for the first quarter of 2023 was 38.636 million USD, a significant improvement from -81.194 million USD in the same period last year[25] - Financing cash flow for the first quarter of 2023 was 9.701 million USD, compared to 138.912 million USD in the same period last year[25] - Cash and cash equivalents at the end of the first quarter of 2023 were 852.320 million USD, an increase from 794.829 million USD at the beginning of the quarter[25] Assets and Liabilities - Total assets increased by 0.94% to 3,083,794,077.47 yuan compared to the end of the previous year[2] - The company's total assets increased to 3.08 billion yuan, up from 3.05 billion yuan at the beginning of the year[18] - Total liabilities increased to 902.18 million yuan, up from 870.02 million yuan at the beginning of the year[18] - The company's total equity decreased slightly to 2.18 billion yuan, down from 2.18 billion yuan at the beginning of the year[18] - The company's inventory decreased to 192.77 million yuan, down from 202.40 million yuan at the beginning of the year[17] - The company's accounts receivable increased to 359.72 million yuan, up from 331.45 million yuan at the beginning of the year[17] - The company's long-term loans decreased to 133.00 million yuan, down from 149.00 million yuan at the beginning of the year[18] R&D and Expenses - R&D expenses decreased by 34.81% to 15,677,120.11 yuan due to different stages of R&D projects[9] - R&D expenses for the first quarter of 2023 were 15.677 million USD, a decrease from 24.047 million USD in the same period last year[21] - Sales expenses for the first quarter of 2023 were 125.912 million USD, an increase from 113.151 million USD in the same period last year[21] - Management expenses for the first quarter of 2023 were 28.511 million USD, a decrease from 29.479 million USD in the same period last year[21] Financial Expenses and Income - Financial expenses showed a significant improvement, with a net income of 2,981,316.04 yuan compared to an expense of 1,858.23 yuan last year[9] Government Subsidies - The company received government subsidies of 10,930,854.65 yuan during the reporting period[4] Shareholders and Ownership - The number of ordinary shareholders at the end of the reporting period was 34,995[12] - Guangxi Wuzhou Zhongheng Group Co., Ltd. holds 23.43% of the company's shares, making it the largest shareholder[12] Product and Regulatory Approvals - The company's product, Tranexamic Acid Injection, was selected in the 8th National Drug Centralized Procurement[14] - The company received approval from the National Medical Products Administration for the transfer of the drug approval of Triptorelin Acetate Injection[14] Audit Status - The company's first quarter report for 2023 was not audited[26]

证券代码：300006 证券简称：莱美药业 重庆莱美药业股份有限公司 投资者关系活动记录表 编号：2023-001 | 投资者关系活动类 | □特定对象调研 □分析师会议 | | --- | --- | | 别 | □媒体采访 √业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及人 | 线上参与公司莱美药业"2022 年度网上业绩说明会"的 | | 员姓名 | 投资者 | | 时间 | 2023 年 4 月 4 日（星期二）下午 15:00-17:00 | | 地点 | "莱美药业投资者关系"微信小程序 | | 上市公司接待人员 | 董事长：梁建生先生 | | 姓名 | 副董事长、副总经理：冷雪峰先生 | | | 独立董事：陈耿先生 | | | 总经理：邱戎钊先生 | | | 财务总监：赖文女士 | | | 董事会秘书、副总经理：崔丹先生 | | | 保荐机构代表：阎华通先生 | | | 公司于 2023 年 4 月 4 日（星期二）15:00-17:00 通 过约调研平台在"莱美药业投资者关系"微信小程序举 | | ...

Financial Performance - The net profit attributable to shareholders for 2022 was -68.71 million yuan, primarily impacted by national centralized procurement policies and continued high R&D investment[5]. - The company's operating revenue for 2022 was ¥884,586,776.10, a decrease of 27.80% compared to ¥1,225,224,188.67 in 2021[15]. - The net profit attributable to shareholders was -¥68,709,119.36, improving from -¥100,528,177.01 in 2021[15]. - The net cash flow from operating activities was ¥57,133,949.52, down 47.24% from ¥108,281,302.47 in 2021[15]. - The total assets at the end of 2022 were ¥3,054,984,574.17, an increase of 4.38% from ¥2,926,773,933.76 at the end of 2021[15]. - The net assets attributable to shareholders decreased by 1.48% to ¥2,124,446,116.48 from ¥2,156,345,435.92 in 2021[15]. - The company reported a basic earnings per share of -¥0.0651, an improvement from -¥0.1010 in 2021[15]. - The company received government subsidies amounting to ¥53,912,277.96 in 2022, compared to ¥59,795,254.67 in 2021[21]. - The company reported a significant decline in the medical circulation segment, with revenue of ¥93,003,518.09, a decrease of 30.95% from ¥134,697,425.74 in the previous year[46]. - The company reported a total of 70,130,000 CNY in debt repayment, with a completion rate of 100.19%[77]. Research and Development - The company’s R&D investment remains significant, reflecting its commitment to innovation despite financial losses[5]. - The company has established a multi-level research and innovation system to enhance its competitive edge in the pharmaceutical market[30]. - The company is focusing on the development of innovative technologies such as cell immunotherapy and nano carbon iron, while also actively seeking quality projects through external investment platforms[28]. - The company is currently developing multiple key products, including omeprazole magnesium and terlipressin injections, with several projects in the application stage[42]. - The company has several products under research and development, including personalized tumor vaccines and anti-fibrosis therapies, indicating a focus on innovative treatments[42]. - The company has 119 R&D personnel, with a proportion of 13.15% of total employees, up from 12.73% in 2021[61]. - The company’s R&D investment amounted to ¥102,161,660.16 in 2022, representing 11.55% of its operating revenue, an increase from 9.63% in 2021[61]. Market Position and Strategy - The company continues to explore market expansion opportunities and strategic partnerships to enhance its competitive position[5]. - The company aims to optimize its product structure and strengthen its market share in key segments through a dual-engine sales model of "hospital + OTC"[33]. - The company plans to enhance terminal market development and accelerate the establishment of OTC marketing channels to mitigate the impact of centralized procurement on product sales[33]. - The company aims to achieve registration for several new products, including the Esomeprazole Magnesium Enteric-coated Tablets and the Injection of Terlipressin, to expand its offerings[60]. - The company aims to enhance its medical device segment, focusing on the development of a disposable visual endoscope to replace imported products[44]. - The company is committed to high-quality development and innovation-driven growth as its fundamental motivation[92]. - The company aims to maintain a leading position in the specialty and anti-infection disease sectors, focusing on upgrading traditional pharmaceutical industries in China[92]. Governance and Compliance - The management team remains committed to ensuring the accuracy and completeness of financial reporting and disclosures[5]. - The company emphasizes investor relations management, actively engaging with investors through various platforms and events to enhance communication[108]. - The company has implemented a robust internal control system to enhance governance and compliance with relevant laws and regulations[106]. - The company has established a comprehensive information disclosure management system to ensure timely and accurate communication with all stakeholders[107]. - The company has a clear and transparent process for the selection and appointment of directors, ensuring compliance with legal requirements[106]. - The company has maintained effective internal controls related to financial reporting as of December 31, 2022, with no significant deficiencies identified[163]. Environmental Responsibility - The company complies with various environmental protection laws and standards, including the Comprehensive Emission Standard for Air Pollutants[165]. - Laime Longyu's wastewater treatment system has a capacity of 500m³/d, achieving a removal efficiency of 95% using iron-carbon physical reduction and ABR biochemical treatment processes[168]. - In 2022, Laime Longyu's wastewater and exhaust gas emissions met standards 100% of the time throughout the year[168]. - The company has implemented a self-monitoring plan for pollutant emissions, with regular testing conducted by a qualified third-party organization[170]. - The company actively engages in social responsibility, ensuring the protection of shareholder and employee rights[172]. Challenges and Risks - The company is exposed to risks related to industry policies, drug price reductions, product quality, technology development, and external investments[6]. - The company faces challenges from intensified competition and regulatory changes in the pharmaceutical industry, necessitating innovation and strategic adaptation[26]. - The company faces industry policy risks due to increasing regulatory requirements, which may impact production, research, and distribution processes[98]. - The company is exposed to drug price risks as centralized procurement policies may lead to significant changes in bidding and pricing, potentially compressing profit margins[98]. Subsidiaries and Investments - The company added four new subsidiaries during the reporting period, including Chongqing Laimei Zhenyu Pharmaceutical Co., Ltd.[54]. - The company has established a partnership with AglaeaPharma to develop a multi-target small molecule drug screening platform and early disease detection technologies[43]. - The company has completed the use of raised funds totaling CNY 106,451,000.00 as of December 31, 2022[76]. - The company has confirmed that there were no non-operating fund occupations by controlling shareholders or other related parties during the reporting period[191]. Human Resources - The total number of employees at the end of the reporting period was 905, with 445 in the parent company and 460 in major subsidiaries[150]. - The employee composition includes 151 production staff, 221 sales personnel, and 257 technical staff, reflecting a diverse workforce[150]. - The company has a remuneration management system that determines compensation based on performance, work ability, and job responsibilities[138]. - The company has not reported any penalties from securities regulatory agencies for its directors and supervisors in the past three years[137].

为便于广大投资者进一步了解公司经营情况，公司将于2023年4月4日（星期 二）15:00至17:00在"莱美药业投资者关系"小程序举行"2022年度网上业绩说 明会"。本次网上业绩说明会将采用网络远程方式举行，投资者可登陆"莱美药 业投资者关系"小程序参与互动交流。为广泛听取投资者的意见和建议，现提前 向投资者征集问题，投资者可通过以下方式提出所关注的问题，提问通道自本公 告发出之日起开放。 证券代码：300006 证券简称：莱美药业 公告编号：2023-014 重庆莱美药业股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重庆莱美药业股份有限公司（以下简称"公司"）于2023年3月18日在巨潮 资讯网（http://www.cninfo.com.cn）披露了《2022年年度报告》。 重庆莱美药业股份有限公司 董事会 2023 年 3 月 17 日 参与方式：在微信小程序中搜索"莱美药业投资者关系"或者用微信扫描以 下二维码： 依据提示，投资者授权登入"莱美药业投资者关系"小程序后，即可参与交 流。 出席本 ...

证券代码：300006 证券简称：莱美药业 重庆莱美药业股份有限公司投资者关系活动记录表 编号：2020-001 | --- | --- | --- | |-------------------|---------------------------------|----------------------------------------------------| | | R 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | 投 资 者 关 系 活 | □ 新闻发布会 | □ 路演活动 | | 动类别 | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | | | 天风证券股份有限公司、西南证券股份有限公司、中泰证 | | | | 券股份有限公司、川财证券有限责任公司、光大证券股份 | | | | 有限公司、安信证券股份有限公司、国泰君安证券股份有 | | | | 限公司、银华基金管理股份有限公司、上海槐南资产管理 | | | | 有限公司、广州中羲资产管理有限公司、西藏文储投资基 | | 参 与 单 位 名 称 | | 金管理有限公司、北 ...

Group 1: Financial Performance - The company's estimated revenue for 2020 is between 1.55 billion to 1.65 billion CNY, with a net loss attributable to shareholders estimated between 2.7 billion to 3.3 billion CNY [1] - The main reasons for the loss in 2020 include asset impairment totaling approximately 250 million CNY and the impact of development expenses being capitalized [1][2] - The COVID-19 pandemic led to a decrease in revenue by approximately 200 million to 300 million CNY due to reduced market demand [2] Group 2: Strategic Focus and Development - The company plans to focus its resources on oncology, gastrointestinal, and ophthalmology sectors [2] - A total of 460 million CNY in development expenses will be transferred to current R&D costs due to the termination of certain research projects [2] - The company is accelerating the development of its ophthalmology products in collaboration with Eye Hospital [3] Group 3: Asset Management and Corporate Governance - The company has completed the transfer of equity in two subsidiaries as part of its asset disposal strategy [3] - The company is in the process of issuing shares to specific investors, aiming to raise 1 billion CNY for debt repayment and working capital [2] - The introduction of state-owned shareholders is expected to enhance corporate governance and internal control [2] Group 4: Research and Innovation - The company is increasing investment in innovative research, particularly in tumor immunotherapy and targeted drug platforms [3] - The thyroid disease management platform has been established to enhance the company's position in the thyroid sector [3][4] - The company is developing a personalized cell therapy product for advanced ovarian cancer, which has completed pharmaceutical research [4] Group 5: Market Response and Challenges - The company has adapted its sales strategy in response to national drug procurement policies, including changes in sales management and expanding OTC sales channels [4] - The company does not meet the criteria for being classified as ST (Special Treatment) despite consecutive years of losses, as its revenue exceeds 100 million CNY [5]

Financial Performance - The company's revenue for Q3 2022 was ¥264,421,982.22, a decrease of 5.47% compared to the same period last year, and a total revenue of ¥670,853,551.45 for the year-to-date, down 24.77%[4] - The net profit attributable to shareholders for Q3 2022 was ¥11,698,716.60, while the year-to-date net profit was -¥37,373,010.95, reflecting a significant decline of 287.15%[4] - The basic earnings per share for Q3 2022 was ¥0.0111, compared to -¥0.0354 for the same period last year, indicating a decrease of 272.68%[4] - Total operating revenue for the third quarter was ¥670,853,551.45, a decrease of 24.7% compared to ¥891,700,644.80 in the same period last year[23] - The company reported an operating loss of ¥66,999,884.21, compared to an operating profit of ¥25,717,051.29 in the previous year[23] - Net profit for the period was a loss of ¥46,070,929.86, contrasting with a profit of ¥25,413,513.35 in the same quarter last year[23] - The net profit for the third quarter of 2022 was -44,728,469.91 CNY, compared to a net profit of 16,959,509.20 CNY in the same period last year, indicating a significant decline[24] - The company reported a basic and diluted earnings per share of -0.0354 CNY, compared to 0.0205 CNY in the same period last year[24] Assets and Liabilities - The company's total assets at the end of Q3 2022 were ¥3,037,979,049.22, an increase of 3.80% from the end of the previous year[4] - Total assets reached ¥3,037,979,049.22, up from ¥2,926,773,933.76, indicating a growth of 3.8%[21] - The company’s total liabilities increased to ¥833,343,198.44, compared to ¥714,647,217.06, reflecting a rise of 16.6%[21] - The company’s total current assets increased to ¥1,795,368,277.29 from ¥1,726,995,266.10, a growth of 3.9%[20] Cash Flow - Cash flow from operating activities for the year-to-date was -¥26,539,836.25, a decline of 140.08% compared to the previous year[11] - The operating cash flow for the period was -26,539,836.25 CNY, a decrease from 66,213,762.66 CNY in the previous year, reflecting a negative cash flow situation[27] - The total cash inflow from operating activities was 1,071,511,372.34 CNY, down from 1,266,731,649.78 CNY year-over-year, indicating a decrease of about 15.4%[27] - The total cash outflow from operating activities was 1,098,051,208.59 CNY, a decrease from 1,200,517,887.12 CNY in the previous year[27] - The company reported a cash and cash equivalents balance of 686,921,451.70 CNY at the end of the period, an increase from 617,860,422.49 CNY at the end of the previous year[28] - Cash and cash equivalents increased to ¥738,378,951.70 from ¥559,430,726.55, representing a growth of 32.0%[20] - The net cash flow from financing activities was 177,280,866.53 CNY, compared to 135,025,164.38 CNY in the same period last year, showing an increase of approximately 31.4%[28] - The company received 351,999,999.00 CNY in borrowings during the period, a significant increase from 91,000,000.00 CNY in the previous year[28] Investments and Acquisitions - The company reported a significant increase in long-term equity investments by 45.80%, totaling ¥136,649,586.16, due to increased external investments[8] - Long-term equity investments rose to ¥136,649,586.16 from ¥93,724,606.83, marking an increase of 46.0%[20] - The company acquired all tangible and intangible assets related to the injection of Triptorelin Acetate from Hainan Shuangcheng Pharmaceutical Co., Ltd. for RMB 28.8 million[15] - The company is actively involved in strategic partnerships and acquisitions to enhance its market position and product portfolio[15] Regulatory Approvals - The company received drug registration certificates for two specifications of Esomeprazole Magnesium Enteric-coated Capsules (20mg and 40mg) from the National Medical Products Administration[16] - The company received approval for two specifications of Tranexamic Acid Injection (5ml: 0.25g and 5ml: 0.5g) after passing the consistency evaluation of generic drug quality and efficacy[16] - The company received approval for the injection of Fludarabine Phosphate (50mg) after passing the consistency evaluation of generic drug quality and efficacy[17] - The company has received various approvals for its pharmaceutical products, indicating ongoing expansion in its product offerings[16][17] Legal Matters - The company recognized a net loss of RMB 35,377,357.50 based on a first-instance judgment regarding a lawsuit related to the exclusive sales agency rights of Tadalafil[17] - The second-instance judgment of the lawsuit resulted in an impact of RMB 21 million on the company's non-operating income for the current period[17] Research and Development - Research and development expenses for the quarter were ¥54,423,054.23, slightly up from ¥51,915,525.42, indicating a focus on innovation[23] Shareholder Information - The company has a total of 128,700,000 shares held by Qiu Yu, representing a significant portion of its equity[19]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥406,431,569.23, a decrease of 33.59% compared to ¥611,968,335.48 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was a loss of ¥49,071,727.55, a decline of 251.49% from a profit of ¥32,392,702.44 in the previous year[19]. - The net cash flow from operating activities was -¥64,318,129.56, representing a decrease of 799.77% compared to ¥9,191,375.61 in the same period last year[19]. - The basic earnings per share were -¥0.0465, down 234.01% from ¥0.0347 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was -¥57,102,521.52, compared to -¥29,349,737.60 in the same period last year[19]. - The company's operating revenue for the first half of 2022 was 406.43 million yuan, a decrease of 33.59% compared to the same period last year[29]. - The net profit attributable to shareholders for the first half of 2022 was -49.07 million yuan, primarily impacted by national centralized procurement policies, increased R&D investment, and increased credit impairment losses[29]. - The company reported a significant reduction in financial expenses by 98.10%, down to ¥361,756.76 from ¥19,020,080.57, due to a substantial decrease in financing scale during the reporting period[38]. - The company reported a net loss of ¥-461,621,900.59, worsening from a loss of ¥-412,550,173.04 at the beginning of the year[148]. - The net profit for the first half of 2022 was -31,261,656.42 CNY, a significant decline compared to a net profit of 65,789,333.25 CNY in the same period of 2021[160]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,005,382,770.61, an increase of 2.69% from ¥2,926,773,933.76 at the end of the previous year[19]. - The total assets of the company amounted to CNY 2.78 billion, compared to CNY 2.71 billion in the previous year, indicating a growth of 2.8%[155]. - Total liabilities increased to ¥846,549,071.77 from ¥714,647,217.06, which is an increase of about 18.5%[148]. - The company's total equity decreased to ¥2,158,833,698.84 from ¥2,212,126,716.70, a decline of approximately 2.4%[148]. - The total equity of the company decreased to CNY 2.34 billion from CNY 2.37 billion, a decline of 1.3%[155]. - The total amount of restricted assets at the end of the reporting period was CNY 436,188,268.25, including CNY 55,842,809.08 in cash, CNY 127,432,231.92 in fixed assets, and CNY 50,796,839.82 in intangible assets[48]. Research and Development - The company has a diverse product portfolio, focusing on chemical pharmaceuticals, including specialized drugs for oncology and digestive systems[27]. - The company is actively pursuing strategic collaborations and equity investments to enhance its R&D capabilities and product offerings[27]. - Research and development investment increased by 40.36% to ¥50,889,028.55 from ¥36,255,308.10 in the previous year, reflecting the company's commitment to enhancing its R&D capabilities[38]. - The company is actively developing a pipeline of new products, including 19 projects in various stages, such as the approval of Esomeprazole Magnesium and ongoing applications for several anti-tumor drugs[32]. - The company plans to enhance its market position by leveraging its research and development capabilities and optimizing its product structure in key therapeutic areas[31]. Market and Operational Strategy - The company has implemented a comprehensive sales strategy, focusing on expanding market share and brand influence through targeted promotions and market penetration[28]. - The company is focusing on expanding its OTC marketing channels and promoting community pharmacies to mitigate the impact of centralized procurement policies[32]. - The company is adapting to the evolving pharmaceutical landscape, focusing on innovation-driven development in response to industry policy changes[31]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and distribution channels[93]. - The company plans to expand its market presence by launching new products in the second half of 2022[172]. Risks and Challenges - The company faces operational risks due to the COVID-19 pandemic, industry policies, drug price reductions, and product quality safety[5]. - Industry policy risks are significant, with new regulations impacting production, research, and distribution processes, necessitating strategic adjustments[68]. - The company is at risk of drug price reductions due to centralized procurement policies, which could compress profit margins[68]. - The company emphasizes technology development as a core competitive advantage, facing high costs and risks associated with new product development[69]. - Quality control remains a priority, with no reported economic disputes due to product quality issues, although risks persist[69]. Shareholder and Governance - The company emphasizes the protection of shareholder rights, ensuring equal treatment and communication with investors[85]. - The company has made commitments to avoid competition with its controlling entities, ensuring that new business opportunities are first offered to relevant parties[89]. - The company has maintained its commitment to independent operations and financial autonomy for Lai Mei Pharmaceutical, ensuring no interference in major business decisions[92]. - The company has guaranteed that it will not engage in any business activities that directly or indirectly compete with Lai Mei Pharmaceutical[92]. - The company has ensured that all related party transactions are disclosed in accordance with regulations[91]. Environmental Compliance - The company has established a wastewater treatment system with a capacity of 500m³/d and seven exhaust gas treatment devices, all operating normally in the first half of 2022[81]. - The company reported a total COD discharge of 5.67636 tons and ammonia nitrogen discharge of 283.2 tons per year, adhering to pollution discharge standards[81]. - The company has implemented a self-monitoring plan for environmental pollutants, ensuring compliance with discharge permits through third-party testing[83]. - The company has not faced any administrative penalties for environmental issues during the reporting period[84]. Future Outlook - The company plans to continue its focus on R&D for new products and technologies to enhance market competitiveness[176]. - The company aims to maintain a stable dividend distribution policy to ensure shareholder returns[176]. - The overall financial health of the company remains strong, with a focus on sustainable growth strategies moving forward[176]. - Future guidance estimates a revenue growth of 20% for the next fiscal year, driven by new product introductions and market expansion[94].